Floatz logo

Albutrepenonacog Alfa

Hemophilia

National Taiwan University Hospitalprotein_peptidePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

17 Active assets in the Hemophilia cohort.

Asset / SponsorPhaseRating
ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT
Chulalongkorn University
Phase 4BB
Stsp-0601 For
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 3BB
Immunoglobulin G1, Anti-(Human Tissue Factor Pathway Inhibitor) (Human Monoclonal Pf-06741086 .Gamma.1-Chain), Disulfide With Human Monoclonal Pf-06741086 .Lambda.-Chain, Dimer
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BB
Ribavirin
Kenneth Sherman
Phase 4BB
Factor Viii Inhibitor Bypassing Fraction
Baxalta now part of Shire
Phase 3BB

View all 32 →

Same molecule, other indications

Albutrepenonacog Alfa is also rated in:

hemophilia BActive
BBB
Indicative · Phase 3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →